SCAND3 and hepatocellular carcinoma: When we combined the two methylation markers, the methylation ratios of the two-gene panel “SCAND3 + Myo1g” were significantly different for comparisons between the four groups and are as follows: 92.73% in HCC patients, 36.53% in LC patients, 12% in BLD cases, and 8.16% in HC, respectively.